Rogel Cancer Center establishes new Center of Excellence for Cancer Immunology and Immunotherapy

Media contact: Nicole Fawcett, 734-764-2220 |  Patients may contact Cancer AnswerLine 800-865-1125

A new Center of Excellence for Cancer Immunology and Immunotherapy (CECII) within the Rogel Cancer Center will widen U-M’s scope of cancer immunological clinical research, positioning the institution as a global leader in this hot area of cancer research. The center will be led by Weiping Zou, M.D., Ph.D.

CECII scientists and physicians will concentrate on immune subsets and immune-associated gene profiles in diseased models and cancer patients, studying the immune system and the cancer inflammatory process. They will look to see how these contribute to the origin and development and therapy of cancer. CECII will also train prospective leaders in basic and translational immunology research.

The center will focus on interdisciplinary collaboration, research translation and education to enhance human cancer immunology research and improve care for cancer patients. Membership in CECII is open to faculty at U-M who contribute on some level to the center’s overall mission in the areas of research, patient care or education. Members will have access to shared resources that facilitate the work, including shared research grants, research reagents, methods, and models.

For more information, visit the CECII website.

Written by Hannah Schweitzer, Rogel Cancer Center Communication